Research and application of genomic medicine in lung disease during the past century has clarified our understanding and focus on specific phenotypes, helping clinicians tailor treatment for individual patients. Cystic fibrosis and lung cancer have been researched extensively; specific genotypes have been instrumental in precision medicine to treat these lung diseases. Asthma and chronic obstructive pulmonary disease are more complex and heterogeneous in their pathogenesis, genotypic profile, and phenotypic expression, making treatment more difficult with increasing disease severity. This article focuses on the evolving state of the science of precision medicine in lung cancer, chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The body of knowledge in lung disease is growing related to pharmacogenomics, clinical guidelines, genome editing, and approaches to genomic health that will guide clinical treatment options, reduce risk, and promote health.
Skip Nav Destination
Article navigation
Spring 2018
SYMPOSIUM: Genomics and Precision Medicine|
March 15 2018
Lung Disease and Genomics
Kenneth Wysocki, PhD, FNP-BC
Kenneth Wysocki, PhD, FNP-BC
Kenneth Wysocki is a Family Nurse Practitioner, Phoenix, AZ (doctorken@kenwysocki.com).
Search for other works by this author on:
AACN Adv Crit Care (2018) 29 (1): 74–83.
Citation
Kenneth Wysocki; Lung Disease and Genomics. AACN Adv Crit Care 15 March 2018; 29 (1): 74–83. doi: https://doi.org/10.4037/aacnacc2018378
Download citation file:
Sign in
Don't already have an account? Register
AACN Account
Sign InSign in via your Institution
Sign in via your InstitutionShort-term Access
Purchase short-term access on a pay-per-article or pay-per-issue basis.
$15 72 - hour single article access $30 7 - day full issue access